Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ticagrelor

ticagrelor

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ticagrelor

57 trials tracked of ticagrelor: 41 in phase 3 or 4 and 18 with published results. The most-cited published study has 658 citations.

57Trials tracked
41Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 31 Phase 3 10 Phase 2 10 Phase 1 4 Other / NA 2
  1. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 658 cited
  2. Phase 4 Tailored Antiplatelet Therapy Following PCI Completed · 402 cited
  3. Phase 4 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery Completed · 237 cited
  4. Phase 3 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] Completed · 104 cited
  5. Phase 3 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death Completed · 99 cited
  6. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 74 cited
Show 44 more trials
  1. Phase 4 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Completed · 56 cited
  2. Phase 3 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation Completed · 50 cited
  3. Phase 4 The Effect of IV Cangrelor and Oral Ticagrelor Study Completed · 46 cited
  4. Phase 4 Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine Completed · 36 cited
  5. Phase 4 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: Completed · 27 cited
  6. Phase 4 Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Completed · 22 cited
  7. Phase 3 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease Completed · 13 cited
  8. Phase 3 Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes Completed · 13 cited
  9. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  10. Phase 4 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis Completed · 9 cited
  11. Phase 4 Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease Completed · 8 cited
  12. Phase 4 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention Completed · 7 cited
  13. Phase 4 Brilinta DaYu Study Completed
  14. Phase 4 Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI Completed
  15. Phase 4 Clopidogrel Versus Ticagrelor in Type-2 Diabetes Completed
  16. Phase 4 Antiplatelet Therapy After Cardiac Arrest Completed
  17. Phase 4 P3AMI Antiplatelet Trial Completed
  18. Phase 4 Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study Completed
  19. Phase 4 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction Completed
  20. Phase 4 Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI Completed
  21. Phase 4 NIRS Ticagrelor Evaluation Completed
  22. Phase 4 Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis Completed
  23. Phase 4 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) Completed
  24. Phase 4 Chewed Versus Integral Pill of Ticagrelor Completed
  25. Phase 4 CES1 Crossover Trial of Clopidogrel and Ticagrelor Completed
  26. Phase 4 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin Completed
  27. Phase 4 Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction Completed
  28. Phase 4 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Completed
  29. Phase 4 A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS Completed
  30. Phase 4 A Pharmacodynamic Study With Ticagrelor in African American Patients Completed
  31. Phase 4 A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) Completed
  32. Phase 4 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients Completed
  33. Phase 3 Efficacy and Safety of Low-dose Ticagrelor Completed
  34. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  35. Phase 3 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Completed
  36. Phase 2 Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis Completed
  37. Phase 2 Cangrelor Ticagrelor Transition Study Completed
  38. Phase 2 Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion Completed
  39. Phase 2 A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome Completed
  40. Phase 2 A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants Completed
  41. Phase 2 Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study Completed
  42. Phase 2 A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease Completed
  43. Phase 2 An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease Completed
  44. Phase 2 A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders Completed

Showing the 50 most-cited and recently-updated of 57 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Early dual antiplatelet therapy improves outcomes after ischaemic stroke thrombolysis
Neurology RCT
Early dual antiplatelet therapy improves outcomes after ischaemic stroke thrombolysis Stroke Patients Gain Better Recovery With Early Double Blood Thinner Combo
A Chinese trial found that starting aspirin and ticagrelor within six hours after thrombolysis boosted excellent functional outcomes at 90 d…
Adding a second blood thinner within hours helps more stroke patients regain full function without raising bleeding risks
May 15, 2026
FDA approves ticagrelor for multiple indications in cardiology and neurology
Cardiology FDA Approval
FDA approves ticagrelor for multiple indications in cardiology and neurology Brilinta Now Approved for Stroke Prevention in Three Key Groups
The FDA approved ticagrelor (Brilinta) for patients with ACS, CAD at high risk, and acute ischemic stroke or high-risk TIA. In ACS, it was s…
A widely used heart medication now has FDA approval to prevent first strokes in people with diabetes and to protect against repeat strokes a…
FDA May 14, 2026
Tailored antiplatelet strategy showed no benefit over standard dual therapy in high-risk PCI patients
Cardiology RCT
Tailored antiplatelet strategy showed no benefit over standard dual therapy in high-risk PCI patients New heart drug plan failed to beat standard care for high-risk patients
This randomized clinical trial compared a tailored antiplatelet strategy involving early low-dose ticagrelor followed by late de-escalation …
Doctors tested a custom heart drug plan but found standard treatment still works best for high-risk patients
May 5, 2026
Prospective observational study identifies 2,504 potential drug-drug interactions among hospitalized patients with acute coronary syndrome
Drug Pipeline Cohort
Prospective observational study identifies 2,504 potential drug-drug interactions among hospitalized patients with acute coronary syndrome Heart Patients Face Hidden Risks From Common Drug Mixes
This prospective observational cohort study evaluated 371 hospitalized patients with acute coronary syndrome at Assiut University Heart Hosp…
Taking several heart medications at once can create dangerous hidden interactions that increase the risk of treatment failure and hospital s…
Frontiers Apr 19, 2026
Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI
Cardiology RCT
Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI New study shows ticagrelor did not beat prasugrel for heart attack prevention in diabetics
This randomized clinical trial of 1,800 patients with diabetes and multivessel coronary artery disease undergoing PCI compared ticagrelor pl…
For diabetics with heart stents, a new study found ticagrelor offered no clear advantage over prasugrel in preventing death, heart attacks, …
JAMA Cardiol Apr 9, 2026
Adding low-dose rivaroxaban to DAPT did not significantly reduce LV thrombus in anterior STEMI patients
Cardiology RCT
Adding low-dose rivaroxaban to DAPT did not significantly reduce LV thrombus in anterior STEMI patients Adding low-dose rivaroxaban to standard heart attack drugs did not clearly prevent blood clots in the heart
This randomized clinical trial evaluated 560 patients with anterior ST-segment elevation myocardial infarction (STEMI) across 29 centers in …
Adding a low-dose blood thinner to standard heart attack drugs did not clearly prevent dangerous clots in the heart, based on a trial of 560…
JAMA Cardiol Apr 9, 2026
Lp-PLA2 activity does not significantly modify dual antiplatelet therapy efficacy in minor stroke/TIA with CYP2C19 loss-of-function alleles
Neurology RCT
Lp-PLA2 activity does not significantly modify dual antiplatelet therapy efficacy in minor stroke/TIA with CYP2C19 loss-of-function alleles Blood enzyme levels don't change which stroke prevention drug works better, study finds
This subgroup analysis of the CHANCE-2 RCT examined 5919 patients with minor stroke/TIA and CYP2C19 loss-of-function alleles.
A simple blood test for inflammation doesn't predict which stroke prevention drug works best for patients with a specific genetic trait.
Apr 5, 2026
Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI
Cardiology Phase II
Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI Can a single blood thinner prevent heart attacks after stent placement?
A single-center, single-arm, prospective phase II pilot study of 200 patients assessed the initial safety of ticagrelor monotherapy after co…
A new pilot study tests if one blood thinner alone can safely prevent heart attacks and stent clots after stent placement for heart attack p…
CT.gov Mar 30, 2026
Early Aspirin Withdrawal Post-PCI Reduces Bleeding, No MI Increase with P2Y12 Monotherapy
Cardiology Meta-analysis
Early Aspirin Withdrawal Post-PCI Reduces Bleeding, No MI Increase with P2Y12 Monotherapy Could Stopping Aspirin Early Help Heart Patients Avoid Bleeding Risks?
Meta-analysis shows early aspirin withdrawal (≤3 months) post-PCI with ticagrelor/prasugrel reduces bleeding (HR=0.55, 95% CI [0.42, 0.71]; …
Stopping aspirin within three months after a heart procedure reduces bleeding risk without increasing heart attack chances for many patients…
Mar 27, 2026